Lipid lowering in liver and chronic kidney disease

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Lipid lowering, particularly with HMG CoA reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver and kidney disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are not available. In contrast, in chronic kidney disease, dosing of lipid medications may require substantial modification depending on creatinine clearance. There are significant alterations in lipid metabolism in chronic kidney disease with concomitant increases in cardiovascular risk. Some data are available on cardiovascular outcomes with dyslipidemia treatment in renal patients. This review will examine lipid physiology and cardiovascular risk in specific liver and kidney diseases and review the evidence for lipid lowering and the use of statin and non-statin therapies in chronic liver and kidney disease.

Original languageEnglish
Pages (from-to)339-352
Number of pages14
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number3
StatePublished - Jun 2014


  • chronic kidney disease
  • chronic liver disease
  • dyslipidemia
  • end stage renal disease
  • ezetimibe
  • fibrates
  • statins


Dive into the research topics of 'Lipid lowering in liver and chronic kidney disease'. Together they form a unique fingerprint.

Cite this